Collectively, these data implicate the M-CSF/c-Fms signaling axis as a critical pathway underlying the aberrant functioning of Nf1 haploinsufficient osteoclasts and warrant further investigation of c-Fms as a potential therapeutic target for treating NF1 associated osteoporosis and osteopenia. The gene discussed is NF1; the disease is osteoporosis.